AI Science Tracker
EN

Longitudinal DLQI trajectory patterns and early risk updating in telepharmacy-monitored psoriasis.

Affiliation not stated in the reviewed material · 26 Oct 2026 · medicine

Discovery

Longitudinal DLQI trajectory patterns and early risk updating in telepharmacy-monitored psoriasis.

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: Ward clustering of psoriasis quality-of-life trajectories identified three exploratory patterns, including a persistent-burden group; for remission, month-one DLQI updating improved AUROC to 0.753 with calibration, while baseline DLQI alone matched/outperformed ensembles for improvement. This is a retrospective telepharmacy cohort result and shows limited incremental value of complex ML.

Technology: Ward clustering identifies DLQI trajectory groups; repeated-split machine-learning models update psoriasis-remission risk from month-one scores.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Ward clustering identifies DLQI trajectory groups; repeated-split machine-learning models update psoriasis-remission risk from month-one scores.
Limitation / still unknown
Results are limited to the reported models, cohorts, datasets or experiments; broader generalization and clinical or operational benefit were not established.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/digital-health/articles/10.3389/fdgth.2026.1961097/full

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.

Related catalog entries

Links use documented relationships where available, plus shared catalog context. A shared topic or model family does not establish a scientific dependency.